Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.

The Company plans to provide a business update and report first quarter 2026 financial results in a press release on May 7, 2026. Given the investor and analyst meeting on May 14, this quarter the ...

William Blair initiated coverage on Natera Inc. NTRA, highlighting the company's strong positioning in the emerging minimal ...

BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 and ...

Rapport Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision medicines for neurological and psychiatric disorders, is hosting its first Investor and Analyst Day ...